Related references
Note: Only part of the references are listed.Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults
M. J. M. Bonten et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
A review of economic evaluations of 13-valent pneumococcal conjugate vaccine (PCV13) in adults and the elderly
S. Dirmesropian et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2015)
Effect of 13-valent pneumococcal conjugate vaccine on admissions to hospital 2 years after its introduction in the USA: a time series analysis
Lone Simonsen et al.
LANCET RESPIRATORY MEDICINE (2014)
US Hospitalizations for Pneumonia after a Decade of Pneumococcal Vaccination
Marie R. Griffin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Identifying the Interaction Between Influenza and Pneumococcal Pneumonia Using Incidence Data
Sourya Shrestha et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions
Bo-Hyun Cho et al.
VACCINE (2013)
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
Lisa A. Jackson et al.
VACCINE (2013)
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults
Lisa A. Jackson et al.
VACCINE (2013)
Incidence and Cost of Pneumonia in Medicare Beneficiaries
Cindy Parks Thomas et al.
CHEST (2012)
Healthcare utilization and cost of pneumococcal disease in the United States
Susan S. Huang et al.
VACCINE (2011)
Efficacy of pneumococcal vaccination in adults: a meta-analysis
Anke Huss et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2009)
Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia in children and adults
Jennifer C. Nelson et al.
VACCINE (2008)
Vaccines for preventing pneumococcal infection in adults
S. A. Moberley et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2008)
Influenza vaccination - Health impact and cost effectiveness among adults aged 50 to 64 and 65 and older
Michael V. Maciosek et al.
AMERICAN JOURNAL OF PREVENTIVE MEDICINE (2006)
Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales
A Melegaro et al.
VACCINE (2004)
Comparing potential benefits of new pneumococcal vaccines with the current polysaccharide vaccine in the elderly
AM Fry et al.
VACCINE (2002)
Cost-effectiveness of the pneumococcal vaccine in the United States Navy and Marine Corps
PV Pepper et al.
CLINICAL INFECTIOUS DISEASES (2000)